

Clinical Policy: Teprotumumab (Tepezza)

Reference Number: LA.PHAR.465

Effective Date: 09.25.23

Last Review Date: 07.20.23 05.27.24

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

****Please note: This policy is for medical benefit****

Description

Teprotumumab (Tepezza™) is an insulin-like growth factor 1 receptor (IGF-1R) inhibitor.

FDA Approved Indication(s)

Tepezza is indicated for the treatment of thyroid eye disease (TED) regardless of TED activity or duration.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana Healthcare Connections® that Tepezza is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Thyroid Eye Disease (must meet all):

1. Diagnosis of Graves' disease with associated TED (i.e., Graves' ophthalmopathy, Graves' orbitopathy);
2. Prescribed by or in consultation with an ophthalmologist;
3. Age \geq 18 years;
4. One of the following (a or b):
 - a. Member is euthyroid with documentation of a recent (within the last 30 days) free thyroxine (FT4) and total triiodothyronine (T3) or free T3 (FT3) levels within the laboratory defined reference range;
 - b. Member has a recent (within the last 30 days) free thyroxine (FT4) and total triiodothyronine (T3) or free T3 (FT3) levels less than 50% above or below the laboratory defined reference range and is undergoing treatment to correct the mild hypo- or hyperthyroidism to maintain a euthyroid state;
5. Member has not had previous surgical intervention for TED;
6. Member does not require surgical ophthalmological intervention;
7. Failure of a 4-week trial of a systemic corticosteroid (at up to maximally indicated doses), unless ~~clinically significant adverse effects are experienced or all are contraindicated;~~ one of the following (a, b, or c):
 - a. Clinically significant adverse effects are experienced or all are contraindicated;

CLINICAL POLICY

Teprotumumab

- b. Member has significant proptosis (examples may include but are not limited to proptosis ≥ 3 mm above the upper limit for race and sex, or proptosis that impacts activities of daily life [e.g., reading, driving, computer work, and watching television]);
 - c. Member has diplopia;
 - 8. Member has not received ≥ 8 Tepezza infusions (including the initial 10 mg/kg first infusion);
 - 9. Dose does not exceed both of the following (a and b):
 - a. A single 10 mg/kg dose followed by seven 20 mg/kg infusions given every 3 weeks (*see Appendix E for vial rounding recommendations*);
 - b. Vial quantity as identified by the online dose calculator using the member's weight (*see Appendix D*) or as recommended in *Appendix E* for vial rounding.
- Approval duration: 6 months (up to 8 total lifetime infusions)**

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

II. Continued Therapy

A. Thyroid Eye Disease (must meet all):

- ~~1.~~ 1.c Member ~~meets one of the following (a or b); is~~ Currently receiving medication via Louisiana Healthcare Connections benefit or member has previously met initial approval criteria;
 - ~~a. Member is responding positively to therapy as evidenced by a reduction in proptosis ≥ 2 mm;~~
- ~~2.~~ 1. Member has not had previous surgical intervention for TED;
- ~~3.~~ 2. Member does not require surgical ophthalmological intervention;
- ~~4.~~ 3. Member has not received ≥ 8 Tepezza infusions (including the initial 10 mg/kg first infusion);
- ~~5.~~ 4. If request is for a dose increase, new dose does not exceed both of the following (a and b):
 - a. A total of seven 20 mg/kg infusions given every 3 weeks (*see Appendix E for vial rounding recommendations*);
 - b. Vial quantity as identified by the online dose calculator using the member's weight (*see Appendix D*) or as recommended in *Appendix E* for vial rounding.

Approval duration: ~~6 months~~ 1 month (up to 8 total lifetime infusions)

CLINICAL POLICY

Teprotumumab

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – LA.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CAS: clinical activity score

FDA: Food and Drug Administration

GO: Graves' ophthalmopathy

TED: thyroid eye disease

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
prednisone	30 mg/day PO	30 mg/day
methylprednisolone (SOLU-Medrol®)	500 mg IV once weekly for weeks 1 to 6, then 250 mg IV once weekly for weeks 7-12	500 mg/week

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

None reported

Appendix D: General Information

- Use of systemic corticosteroids in TED is supported by the following treatment guidelines:
 - 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy: A combination of IV methylprednisolone and mycophenolate sodium is recommended as first-line treatment. If response to primary treatment is poor and Graves' ophthalmopathy (GO)

CLINICAL POLICY

Teprotumumab

- is still moderate-to-severe and active, teprotumumab is considered a second-line option as longer-term data, availability, affordability, costs, and need for subsequent rehabilitative surgery are pending.
- 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis: In the absence of any strong contraindication to GC, consider for coverage of mild active GO who are treated with RAI, even in the absence of risk factors for GO deterioration (weak recommendation, low-quality evidence). Additionally in mild GO patients who are treated with RAI, steroid coverage is recommended if there are concomitant risk factors for GO deterioration (strong recommendation, moderate-quality evidence).
 - The following link will provide the dose and appropriate vial quantity based on the member's weight (note this does not account for dose rounding recommendations found in *Appendix E* below): <https://www.tepezzahcp.com/starting-patients/dosing-and-administration>

Appendix E: Vial Rounding Recommendations (40 to 170 kg)

Weight Range (kg)	Initial Dose (1 dose) Vial Quantity Recommendation	Maintenance (7 doses total) Vial Quantity Recommendation
40 – 52.5	1	14 (2 vials per dose)
52.6 – 55	1	21 (3 vials per dose)
55.1 – 77.5	2	21 (3 vials per dose)
77.6 – 102.5	2	28 (4 vials per dose)
102.6 – 105	2	35 (5 vials per dose)
105.1 – 127.5	3	35 (5 vials per dose)
127.6 – 152.5	3	42 (6 vials per dose)
152.6 – 155	3	49 (7 vials per dose)
155.1 – 170	4	49 (7 vials per dose)

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
TED	Initial: 10 mg/kg IV one time dose Maintenance: 20 mg/kg IV every 3 weeks for seven infusions	See dosing regimen

VI. Product Availability

Single-dose vial: 500 mg

VII. References

1. Tepezza Prescribing Information. Deerfield, IL: Horizon Therapeutics USA, Inc.; ~~April~~July 2023. Available at: <https://www.hzndocs.com/TEPEZZA-Prescribing-Information.pdf>. Accessed ~~July 20~~October 6, 2023.

CLINICAL POLICY

Teprotumumab

2. NCT03298867 in ClinicalTrials.gov. NIH U.S. National Library of Medicine. Available at: <https://clinicaltrials.gov/ct2/show/NCT03298867?term=NCT03298867&draw=2&rank=1>. Accessed October ~~7, 2021~~ 12, 2023.
3. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. 2020 Jan 23;382(4):341-352.
4. Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017 May 4;376(18):1748-1761.
5. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.
6. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997; 47:9.
- ~~7. Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. NEJM 2017; 376 (18): 1748-1761.~~
- ~~8.~~ 7. Patel KN, Yip L, Lubitz CC, et al. The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. Annals of Surgery: March 2020; 271 (3): e21-e93.
- ~~9.~~ 8. Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. European Journal of Endocrinology: 27 August 2021; 185 (4): G43-G67.
9. Horizon Therapeutics plc announces positive topline data from Tepezza® (teprotumumab-trbw) phase 4 clinical trial in patients with chronic/low clinical activity score (CAS) thyroid eye disease (TED). Press Release; Horizon Therapeutics. April 10, 2023. Available at: <https://finance.yahoo.com/news/horizon-therapeutics-plc-announces-positive-120000335.html>. Accessed October 12, 2023.
10. Burch HB, Perros P, Bednarczuk T, et al. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid: 12 Dec 2022. 32 (12): 1439-1470.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J3241	Injection, teprotumumab-trbw, 10 mg

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Policy created	05.01.23	

CLINICAL POLICY

Teprotumumab

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Added “regardless of TED activity or duration” to approved indication. Removed CAS score requirements. Removed general information on CAS scores. Reviewed and updated references.	07.20.23	<u>09.25.23</u>
<u>For corticosteroid redirection added additional bypass for significant proptosis and diplopia consistent with 2022 ATA recommendations; for continuation of therapy reduced approval duration to 1 month; references reviewed and updated.</u>	<u>05.27.24</u>	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to

CLINICAL POLICY

Teprotumumab

recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2024⁴³ Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.